---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-23-000061"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2023-04-25T23:59:59+00:00"
generated_at: "2026-06-16T16:23:28.576874+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BeiGene reports 2022 revenue of $1.42B, R&D spend $1.64B in STAR Market filing

## Summary
- Total revenue $1.416B (2021: $1.176B); China revenue $840M (67.1% margin), Ex-China $576M (98.3% margin).
- R&D expenses $1.641B vs $1.459B in 2021; key product spend: Zanubrutinib $127M, Tislelizumab $88.9M, Ociperlimab $106.6M.
- Production/sales/inventory: 3.28M vials produced, 2.67M sold, 1.54M in stock as of Dec 31, 2022.
- Filed PRC GAAP vs U.S. GAAP reconciliation; differences in share-based comp (accelerated vs straight-line) and lease accounting.

## SEC filing metadata
- accession: 0001651308-23-000061
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2023-04-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000061/0001651308-23-000061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000061/bgne-20230425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-23-000061
- JSON: https://secwatch.observer/filing/0001651308-23-000061.json
- Plain text: https://secwatch.observer/filing/0001651308-23-000061.txt

## Key facts
- Earnings Releases
  BeOne Medicines Ltd. reported the year ended December 31, 2022 results: revenue 1,415,921.
  - Period: the year ended December 31, 2022
  - Revenue: 1,415,921
  - Result: reported results
  source text: For the year ended December 31, 2022 For the year ended December 31, 2021 By Region Revenue COGS Gross Margin ratio Revenue COGS Gross Margin ratio China 840,032 276,729 67.1% 517,173 162,976 68.5% Ex-China 575,889 9,746 98.3% 659,110 1,930 99.7% Total 1,415,921 286,475 1,176,283 164,906
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000061/0001651308-23-000061-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.